Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors | Zendy

Hagop M. Kantarjian | Zendy; Harry P. Erba | Zendy; David F. Claxton | Zendy; Martha Arellano | Zendy; Roger M. Lyons | Zendy; T.J. Kovascovics | Zendy; Janice Gabrilove | Zendy; Michael Craig | Zendy; Dan Douer | Zendy; Michael B. Maris | Zendy; Stephen H. Petersdorf | Zendy; Paul J. Shami | Zendy; Andrew M. Yeager | Zendy; Stephen Eckert | Zendy; Rekha Abichandani | Zendy; Stefan Faderl | Zendy

Open Access

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

Author(s) -

Hagop M. Kantarjian,

Harry P. Erba,

David F. Claxton,

Martha Arellano,

Roger M. Lyons,

T.J. Kovascovics,

Janice Gabrilove,

Michael Craig,

Dan Douer,

Michael B. Maris,

Stephen H. Petersdorf,

Paul J. Shami,

Andrew M. Yeager,

Stephen Eckert,

Rekha Abichandani,

Stefan Faderl

Publication year - 2009

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2009.23.3130

Subject(s) - medicine , clofarabine , gastroenterology , nausea , rash , neutropenia , myeloid leukemia , tolerability , surgery , vomiting , adverse effect , toxicity , cytarabine

This phase II study assessed clofarabine monotherapy in older adults (>or= 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research